BCMA: A Key Target for CAR-T Therapy in Multiple Myeloma

Author: Senior Product Manager of UA Views：73

Based on the clinical treatment challenges of multiple myeloma (MM), this article systematically elaborates on the limitations of existing therapies and the urgent need for novel immunotherapies. It analyzes the successful experience of CD19 CAR-T in B-cell malignancies and its challenges in MM due to target expression barriers. The molecular characteristics and expression advantages of BCMA as a MM plasma cell-specific surface antigen are discussed, providing a theoretical foundation for its suitability as a CAR-T therapy target.

Recent Advances
Product Information

Recent Advances

BCMA: A Key Target for CAR-T Therapy in Multiple Myeloma

Summary: This article systematically elaborates on the limitations of current therapies and the urgent need for novel immunotherapies based on the clinical challenges of multiple myeloma (MM). It analyzes the success of CD19 CAR-T in B-cell malignancies and its obstacles in MM due to target expression barriers, explores the molecular characteristics and expression advantages of BCMA as a MM plasma cell-specific surface antigen, and argues the theoretical basis for its suitability as a CAR-T target.

1. Current Treatment Landscape and Unmet Needs in Multiple Myeloma

Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of plasma cells in the bone marrow, involving genetic abnormalities, dysregulated bone marrow microenvironment, and impaired immune surveillance. Over the past two decades, the advent of proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies has significantly improved treatment response rates and survival, with some patients achieving deep remission. However, despite initial therapy inducing effective clinical responses, most patients inevitably relapse and become refractory due to residual minimal residual disease and clonal evolution, limiting long-term survival benefits. Thus, there is an urgent clinical need for novel therapeutic strategies, particularly innovative approaches capable of achieving durable immune control.

2. Successes and Limitations of CAR-T Therapy in B-Cell Malignancies

Chimeric antigen receptor T-cell therapy has achieved landmark success in B-cell lineage malignancies. The principle involves genetically engineering T cells to express a chimeric antigen receptor (CAR) composed of an antibody-derived single-chain variable fragment targeting tumor antigens fused to T-cell activation domains, enabling MHC-unrestricted antigen recognition. CD19-targeted CAR-T therapy has demonstrated initial complete response rates of 80%-90% in relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma, with multiple products approved by regulatory agencies.

However, replicating this success in multiple myeloma faces a fundamental obstacle: CD19 is not expressed on malignant plasma cells. CD19 expression begins at the pro-B cell stage and persists through mature B cells but is completely lost upon terminal differentiation into plasma cells. Thus, while anti-CD19 CAR-T cells effectively eliminate normal B cells and B-cell malignancies, they cannot recognize or attack MM cells. This limitation necessitates the search for alternative targets that are highly and specifically expressed on malignant plasma cells and involved in tumor survival regulation.

3. Molecular Characteristics and Normal Tissue Expression of BCMA

B-cell maturation antigen (BCMA), also known as CD269 or TNFRSF17, is a member of the tumor necrosis factor receptor superfamily. Encoded by the TNFRSF17 gene, it is a type I transmembrane glycoprotein whose extracellular domain specifically binds two key ligands—B-cell activating factor and a proliferation-inducing ligand. BCMA-ligand interactions activate signaling pathways such as NF-κB and MAPK, playing a critical role in plasma cell survival and maintenance.

In normal tissues, BCMA exhibits highly restricted expression. It is primarily expressed on plasma cells and a subset of mature B cells but is absent in naive B cells, memory B cells, and most non-hematopoietic tissues. This feature ensures that BCMA-targeted immunotherapy does not affect early B-cell development or humoral immune responses. Notably, BCMA knockout mouse models show that BCMA-deficient individuals appear normal and healthy, with B-cell counts within physiological ranges, but exhibit significantly impaired long-term plasma cell survival. This suggests BCMA functions can be partially compensated and that targeting BCMA will not cause severe "on-target" toxicity.

4. High and Specific Expression of BCMA in Multiple Myeloma

The core advantage of BCMA as an immunotherapy target for MM lies in its high and specific expression on malignant plasma cells. Numerous studies confirm that BCMA RNA is universally detectable in MM cells, and BCMA protein is stably expressed on the surface of bone marrow plasma cells in MM patients. Systematic immunohistochemistry and flow cytometry analyses reveal that over 90% of MM bone marrow specimens are BCMA-positive, with expression levels comparable to or higher than those in normal plasma cells. In contrast, BCMA is largely absent in most normal human tissues, with only weak positivity in some plasma-like cells in the spleen and tonsils. This "restricted in normal tissues, high in tumors" expression pattern mirrors CD19's profile in B-cell malignancies, providing an ideal therapeutic window for CAR-T therapy.

5. Theoretical Basis and Preclinical Evidence for BCMA as a CAR-T Target

Integrating the above molecular characteristics, expression profiles, and functional data, BCMA meets the key criteria for a suitable CAR-T target in MM: its expression in normal tissues is highly restricted to plasma cells and some mature B cells, while it is stably and highly expressed on malignant plasma cells in most MM cases; its involvement in plasma cell survival signaling suggests targeting it may directly impact tumor viability; and the normal phenotype of BCMA knockout animals predicts manageable toxicity.

6. Conclusion

The treatment of multiple myeloma stands at a critical juncture, transitioning from traditional chemotherapy and targeted drugs to cellular immunotherapy. The success of CD19 CAR-T in B-cell malignancies validates this approach, but the absence of CD19 expression in MM plasma cells necessitates alternative targets. BCMA, with its lineage-restricted expression, high positivity in MM malignant cells, and the toxicity profile suggested by knockout models, has emerged as the most promising CAR-T target for MM. Uni offers the FITC-Labeled BCMA/TNFRSF17 Fc Chimera Protein, Human, which features precise molecular design, Fc tag-induced dimerization advantages, and the high brightness and stability of FITC dyes, providing a reliable tool for BCMA-related CAR-T cell screening, target validation, and flow cytometry detection.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next